Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Capozide vs ACE-Hemmer-ratiopharm
NCT04964050Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of captopril + hydrochlorothiazide in hypertension (HTN) (3 arms), sponsored by GSK. Primary endpoints: Maximum observed concentration up to 3 weeks, Area under the concentration-time curve from administration to last quantifiable concentration up to 3 weeks and 1 more. Planned start Apr 2022; status: withdrawn.
02
Drugs
captopril + hydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04964050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964050.